Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: GSK receives marketing authorisation from the European Commission for Revolade (eltrombopag) for low platelet counts


Guru

Status: Offline
Posts: 5627
Date:
RE: GSK receives marketing authorisation from the European Commission for Revolade (eltrombopag) for low platelet counts
Permalink  
 


Yes I don`t know why it`s taken so long to be approved in Europe either.  I notice it`s been approved by NICE for use within the NHS over here in the UK now.   Sounds like it will a very useful medication for certain people, even though it can potentially cause some severe side effects.  I have read about them and so can understand why you wanted to avoid it while on treatment even when your platelets levels dropped so low.

Oh yes, the joys of ageing, I know exactly what you mean!   We`re all in it together, just keep smiling! wink

Thanks Malcolm.

 



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 



Guru

Status: Offline
Posts: 3398
Date:
Permalink  
 

Hi Jill,

I'm amazed that it had never been approved before. It's been available here for at least 5 years. It will be great for those who are deemed 'ineligible' for Rx due to low platelets to get them up to an accepted level (120,000 here).

During Rx, personally, I would not touch the stuff, as there have been too many bad stories. Low platelets during Rx is not life-threatening, and mine dropped to 28,000. That's OK as long as you don't run a risk of injury. The general opinion is that the 'quality' of the platelets is very important. Patients over 65yo produce platelets of lower quality ( my doc used to call them 'home-brand') so older people get purpura and ecchymoses from trivial injuries, despite having a normal platelet count. Another of the joys of aging!  Cheers.



__________________

Geno 1b, IL28B CT,  x3 prior relapser,  ex-cirrhotic, 75 yo, did 48 weeks with Victrelis/Peg./Riba.  VL 1.28m at start, UNDET. at 8 ,12 ,16 ,24 ,30  and 48 weeks.  EOT 15 Feb 2013 , UNDET. at EOT + 28 weeks. SVR!  Still Undet. at EOT +5 years

Malcolm



Guru

Status: Offline
Posts: 5627
Date:
GSK receives marketing authorisation from the European Commission for Revolade (eltrombopag) for low platelet counts
Permalink  
 


GSK receives marketing authorisation from the European Commission for additional Revolade (eltrombopag) indication as the first approved treatment for chronic hepatitis C-associated thrombocytopenia

GlaxoSmithKline plc announced today, 24th September, that the European Commission has granted an additional indication for Revolade (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon (IFN)-based therapy.

See full press release...

http://www.gsk.com/media/press-releases/2013/gsk-receives-marketing-authorisation-from-the-european-commissio1.html

 



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.